Nautilus Biotechnology, Inc.

Good day and thank you for standing by. Welcome to the Nautilus fourth quarter and full year 2024 earnings conference call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jian Yi, Head of Investor Relations.

Thank you. Earlier today, Nautilus released financial results for the quarter ended December 31st, 2024. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to investorrelations at Nautilus.bio. Joining me today from Nautilus are Sujil Patel, co-founder and CEO, Parag Malik, co-founder and chief scientist, and Anna Mowry, chief financial officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast on February 27, 2025. With that, I'll turn the call over to Sujal.

Thanks, Jian, and welcome to everyone joining our Q4 and full year 2024 earnings call. Today, we'll provide a quick look back at our 2024 progress, update you on our work since the last call, and present our fourth quarter 2024 financial results. We'll then, as always, open the call for questions. As you know, our goal at Nautilus is to enable proteomics researchers to study the entirety of the proteome at a depth and breadth never before possible, and to make the creation, accessibility, and use of that higher resolution, higher quality data easy enough that it will be practical for every lab everywhere to accelerate scientific research, enable the discovery of new biomarkers, and ultimately power the development of new therapies and diagnostic tests that will positively impact human health. As you saw in this morning's press release, based on the desire to reduce technical risk and bring to market a product with the greatest possible performance, we now expect that the launch of our proteome analysis platform will occur in late 2026. Parag will provide detail on the rationale for that timeframe in a few moments. Since the achievements of last year serve as a foundation for the work ahead, I want to take a few moments to walk you through some notable recent accomplishments. But before I do, it's important to remember that we'll be discussing the status of our overall platform development initiatives and share detail on progress against each of the platform's modalities, broad scale discovery, which aims to comprehensively quantify the proteome, and targeted quantification, which is currently focused on proteoform detection. While both modalities share the same core platform, each has its own development path. With that said, in 2024, we had a number of key demonstrations and progress with regard to the core platform. Among them, we developed improvements to the scale and quality of our reagent production, an instrument and an assay capable of multi-cycling reagents over many cycles and observing protein binding events at the single molecule level, and software capable of processing the data coming off the instrument and through proprietary bioinformatics algorithms turning that multi-cycle data into biological insight. With regards to our pursuit of broad-scale decoding, we developed a large number of probes that successfully bind epitopes spanning the human proteome. We also performed an ultra-deep characterization of a large number of probes to define detailed binding profiles and kinetics. Lastly, we demonstrated via Western blot that these probes can bind to and differentiate proteins successfully and that the results strongly correlate to our binding models. We also made progress on our integrated proteoform capabilities. At WorldHupo last October, and as Parag reported on our previous call, we shared data on the world's first quantitative measurement of biological variation in tau proteoforms potentially associated with Alzheimer's disease. These preliminary findings have spurred substantive conversations with a number of potential partners interested in exploring tau proteoform landscapes at a resolution never before possible. Armed with the learnings and advances of last year and years prior, we now have greater clarity about what remains to be done to deliver what we believe will be a game-changing product to the market. We're focused on the good that we anticipate our platform can do and confident in our ability to get there. For a more detailed update on our R&D efforts, let me turn the call over to Parag. Parag?